Center for Bionanoengineering and Key Laboratory of Biomass Chemical Engineering of Ministry of Education, College of Chemical and Biological Engineering, Zhejiang University, Zheda Road 38, 310027, Hangzhou, China.
Adv Mater. 2017 Apr;29(14). doi: 10.1002/adma.201606628. Epub 2017 Feb 24.
Current cancer nanomedicines can only mitigate adverse effects but fail to enhance therapeutic efficacies of anticancer drugs. Rational design of next-generation cancer nanomedicines should aim to enhance their therapeutic efficacies. Taking this into account, this review first analyzes the typical cancer-drug-delivery process of an intravenously administered nanomedicine and concludes that the delivery involves a five-step CAPIR cascade and that high efficiency at every step is critical to guarantee high overall therapeutic efficiency. Further analysis shows that the nanoproperties needed in each step for a nanomedicine to maximize its efficiency are different and even opposing in different steps, particularly what the authors call the PEG, surface-charge, size and stability dilemmas. To resolve those dilemmas in order to integrate all needed nanoproperties into one nanomedicine, stability, surface and size nanoproperty transitions (3S transitions for short) are proposed and the reported strategies to realize these transitions are comprehensively summarized. Examples of nanomedicines capable of the 3S transitions are discussed, as are future research directions to design high-performance cancer nanomedicines and their clinical translations.
当前的癌症纳米药物只能减轻不良反应,但不能增强抗癌药物的治疗效果。下一代癌症纳米药物的合理设计应旨在增强其治疗效果。考虑到这一点,本综述首先分析了静脉内给予的纳米药物的典型癌症药物传递过程,并得出结论,该传递涉及五个步骤的 CAPIR 级联,并且每一步的高效率对于保证高的整体治疗效率至关重要。进一步的分析表明,对于纳米药物而言,在每个步骤中最大化其效率所需的纳米特性在不同的步骤中是不同的,甚至是相互矛盾的,特别是作者所说的 PEG、表面电荷、大小和稳定性难题。为了解决这些难题,以便将所有需要的纳米特性整合到一种纳米药物中,提出了稳定性、表面和尺寸纳米特性转变(简称 3S 转变),并全面总结了实现这些转变的报道策略。讨论了能够实现 3S 转变的纳米药物的例子,以及设计高性能癌症纳米药物及其临床转化的未来研究方向。